A study was conducted to describe the genetic diversity of hepatitis C virus (HCV) in a population of positive blood donors from throughout Indonesia. Repeat analysis by reverse transcription-polymerase chain reaction (RT-PCR) of 102 anti-HCV positive samples showed that 67 gave HCV-specific positive signals by the PCR for the 5Ј-untranslated genomic region of HCV. Further genotypic analysis on 64 HCV RNA-positive samples indicated that 57 belonged to the following individual genotypes: 1a, 1b, 2a, 2b, and 3b. The predominant HCV genotypes in this donor population were 1b (57.8 %), 2a (17.2 %), and 3b (10.9 %). The core sequences of the 4 indeterminate samples when aligned with published sequences of various HCV genotypes showed a range of homology from 16.16% to 78.67%. Comparative analysis of genotypic representation from other anti-HCV-positive study populations, including polytransfused pediatric and adult renal dialysis groups, is now being carried out to determine the potential genotypic association with mechanistic HCV spread.
Ever since its molecular characterization in 1989, hepatitis C virus (HCV) has been shown to be the major cause of acute and chronic blood borne non-A non-B hepatitis and the leading cause of chronic liver disease worldwide (for a review see 1, [2] [3] [4] . This initial molecular characterization led to the use of genomic sequence information from reverse transcription-polymerase chain reaction (RT-PCR)-assisted amplified partial and/or full length HCV RNA on viral isolates as a means to classify these isolates into genetic groups, genotypes, and subtypes, and to the definition of primers, probes and first-and second-round PCR techniques to identify, group, and classify known and unknown isolates of HCVs worldwide. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] An accumulation of such sequence information has led to the definition of HCV types, subtypes, and genetic groups. So far, 6 major HCV types and more than 74 different subtypes have been catalogued, and the number continues to grow as new isolates are sequenced and more countries are included in the sampling of HCV. However, whether genetic group, sub-type, and even type influence clinical outcome, response to therapy, and immune response remains to be established. Such sequence information and typing/subtyping data is nonetheless considered important for a number of reasons, some of which include the fact that such databases are critical to 1) the understanding of the global, regional and national epidemiology of HCV virus infection and transmission, 2) the design and evaluation of serologic assays, 3) the rational design of vaccine candidates against these isolates, 4) the study of the differences in the response of such HCV-infected patients to therapy with agents such as interferon-alpha, 17, 18 and 5) the study of the diverse clinical outcomes associated with such diverse viruses. The clinical outcome of HCV infection is markedly variable ranging form subclinical, self-limiting infection to end-stage liver disease with hepatocellular carcinoma. 19 Most individuals who contract HCV infection do not develop clinically recognized symptoms, and a large frequency of HCV-infected individuals become persistently infected; the molecular mechanisms for such viral persistence also remains unknown. It has been hypothesized that such viral persistence may be due to the lack of an effective anti-HCV immune response. The precise epitopes of the viral proteins that are the target of humoral and cellular immune responses also remain unknown. This is partly due to the genetic diversity of the HCV, making it difficult to identify immunodominant T and B cell epitopes.
Hepatitis C virus is an enveloped, positively stranded, linear RNA virus with an approximately RNA genome of 10 kB. 1, 20 The genomic organization of this virus consists of untranslated regions at both the 5Ј (1-341 basepairs) and 3Ј (9372-9401 basepairs) termini flanking a continuous translational open reading frame that codes for the core (342-914 basepairs), the envelope E1 protein (915-1490 basepairs), and a series of a nonstructural (NS) proteins such as the envelope E2/NS1 (1491-2528 basepairs), NS2 (2529-3359 basepairs), NS3 protease/helicase (3360-5186 basepairs), NS4 (5187-6380 basepairs), and the NS5 RNA polymerase (6381-9371 basepairs). 20, 21 Which of these individual proteins and their individual diversity present in a given HCV isolate influences 1) the clinical course of the disease, 2) the outcome of therapy with interferon-alpha, 3) the target of response, 4) the quality of the immune response, and 5) viral transmission and viral persistence remains to be established. With regard to transmission, it is important to note that there has been a marked decrease in the transmission of HCV in the developed world during the past 2-3 decades, and it is currently thought to be primarily associated with a restricted group of injection drug use. 22 Transmission of HCV in the relatively less developed nations and in particular tropical countries is less well understood since most carriers do not present with any readily identifiable risk factors for infection. It has been suspected for some time that use of inadequately sterilized medical equipment is one of the major contributing factors. 23 These facts dictate that there is a need for continuous monitoring of the genetic diversity of HCV isolates specially in countries where there is documented evidence for a high rate of transmission, in countries from which databases for HCV genotypes are limited or not available, and in less developed countries. Our laboratory has been addressing this issue and is in the process have previously documented the prevalence of HCV in a total of 7,572 blood donors from the Indonesian archipelago based on serologic techniques. A study of the identification of HCV genotypes and variants among HCV isolates from a select group of patients with acute hepatitis in a Jakarta, Indonesia hospital and in 3 patients with chronic liver disease has also been performed. 8, 12 However, it was reasoned that such data may be biased and reflect mostly HCV genotypes that have a high predilection for causing disease. The finding of a high prevalence of HCV 1b genotype in samples from the hospital-based study on patients with hepatitis supports this view. It was therefore reasoned that a study of the HCV genotypes and variants in a non-biased blood donor population may provide a more objective analysis of the HCV genotypes and variants prevalent in the Indonesian archipelago. A study was thus conducted on the prevalence of HCV seropositivity among the blood donor population in Indonesia and the results are reported elsewhere. 12 These HCV seropositive samples were then subsequently used to define HCV genotypes and variants. The results of the study of the genotypes and variants in this blood donor population constitute the basis of this report.
MATERIALS AND METHODS

Donor samples.
A total of 7572 blood specimens (6,732 males, 755 females, and 85 unknown) were collected during a survey of a total of 24 blood banks located in 21 of the 27 provinces that comprise the Indonesian archipelago. The collection of blood samples occurred from November 1992 to February 1993. All blood collection in Indonesia is totally voluntary and appropriate locally defined inform consent was duly acquired before obtaining each blood sample. The number of blood samples collected from each of the provinces was proportional to the population of the respective province. Collections were based on period specific activities, and not on any randomized sampling strategy. The mean Ϯ SD age of the study population was 32.91 Ϯ 10.02 years (range ϭ 11-76 years). The mean Ϯ SD age of the males was slightly higher (P Ͻ 0.0001) than that of the females (33.04 Ϯ 9.97 versus 31.79 Ϯ 10.48 years). No adverse effects of blood donation were noted. Standard epidemiologic data (emphasis on identifying standard bloodborne infection transmission risk factors) linked to each specimen collection were collected but without identifiers. All procedures were approved by the Human Investigation Committee of the Naval Medical Research Unit No. 2 prior to the initiation of the study.
Serologic assays. As stated earlier, all 7,572 serum samples were assayed for the presence of antibodies to HCV using a second-generation enzyme immunoassay (EIA) kit (Abbott Laboratories, North Chicago, IL) and the results of this study are reported elsewhere. 21 Results showed that 161 of the 7,572 specimens were positive for antibodies to HCV.
Polymerase chain reaction studies. Serum samples from 102 of the 161 anti-HCV positive samples were available in sufficient volumes to allow for repeated analysis by RT-PCR and were thus further analyzed. Putative viral RNA extracted from these 102 specimens were first subjected to a PCR with primers encompassing the 5Ј-untranslated genomic region (5Ј-UTR) of HCV as previously described 11 using the primer pairs identified as p32/p36 and p33/p48, resulting in 221- and 126-basepair PCR products, respectively. Those samples showing positive results for HCV RNA were then subjected to genotyping with type-specific primers (Table 1) escribed elsewhere by Ohno and others. 5 For those samples that were defined to be of indeterminate genotype with type-specific primers, the core sequences for each was amplified using universal primers, the amplified sequences were cloned and sequenced, and the new sequences were subjected to phylogenetic analysis. The techniques used for this are briefly described below.
Extraction of viral RNA. Viral RNA was extracted from 140 l of serum using the QIAamp HCV kit (Qiagen, Inc., Hilden, Germany), followed by ethanol precipitation. This yielded a volume of 100 l of RNA, of which 4 l was used for reverse transcription.
5-UTR PCR. cDNA was synthesized in a 10-l reaction mixture containing 20 pmol of the outer sense primer (p36), 100 units of MMLV (Gibco-BRL, Gaithersburg, MD), 2 l of 5ϫ first-strand buffer (Gibco-BRL), 5 nmol of each dNTP (Takara, Inc., Tokyo, Japan), and 11 units of RNase inhibitor (Takara, Inc.). The mixture was incubated for 60 min at 42ЊC. It was then amplified in a first-round PCR (94ЊC for 1 min, 55ЊC for 1.5 min, and 72ЊC for 3 min) for 35 cycles in a 50-l reaction mixture that contained 80 pmol of the anti-sense primer (p36) and 80 pmol of the sense primer (p32), 10ϫ PCR buffer, 5 nmol of each dNTP, and 1.25 units of Taq polymerase (Takara, Inc.). The first-round PCR products were subjected to a second round of PCR (94ЊC for 1 min, 55ЊC for 1.5 min, and 72ЊC for 2 min) for 35 cycles in a 50-l reaction mixture that contained 1 l of the firstround PCR product, 40 pmol each of the anti-sense primer (p48) and the sense primer (p33), 10ϫ PCR buffer, 2.5 nmol of each dNTP, and 1.25 units of Taq polymerase (Takara, Inc.).
Genotyping. For the genotyping studies, HCV type-specific primers designed by Ohno and others 5 were used. Briefly, cDNA was synthesized using the universal outer antisense primer AC2 (10 pmol in a 10-l reaction mixture) and the same ingredients as described above for the 5'-UTR PCR. The reaction mixture was incubated 94ЊC for 1 min, 55ЊC for 1 min, and 72ЊC for 1 min for 20 cycles. During the second-round PCR (94ЊC for 1 min, 62ЊC for 1 min, and 72ЊC for 1 min for 20 cycles), 2 different mixtures of antisense type-specific primers were included in the PCR mixture. Mixture 1 contained subtype-specific primers 1b, 2a, 2b, and 3b, whereas mixture 2 contained subtype-specific primers 1a, 3a, 4, 5a, and 6a. A primer concentration of 1 pmol was used for each anti-sense genotype-specific primer ense common primer. The other constituents were similar to those used for the 5'-UTR PCR. Universal primers were used to amplify undetermined HCV subtypes.
Gel electrophoresis. The PCR products were subjected to electrophoresis using a 2% or 3% NuSieve 3:1 agarose gel (FMC Bioproducts, Rockland, ME) for analysis of the 5'-UTR PCR and the genotyping PCR product, respectively. The electrophoresed bands were stained with 0.5 g/ml of ethidium bromide (Merck, Inc., Darmstadt, Germany) and visualized with UV light. Genotype assignment was based on the relative length of the PCR product following the second-round PCR and use of type-specific primers. The primers used for genotyping are described in Table 1 .
Cloning and sequencing. The PCR products that were amplified using the universal primer were cloned into the PCR-11 vector using the TA cloning kit (Invitrogen, Inc.. Groningen, The Netherlands). Plasmids derived were purified using the Qiagen Plasmid mini kit (Qiagen, Inc.) and sequenced. Phylogenetic analysis. This analysis was carried out using the program DNADIST and NEIGHBOR provided with PHYLIP package designed by Felsenstein. 25 
RESULTS
Antibodies to HCV were detected in 161 of the 7,572 blood samples, indicating a prevalence rate of 2.1% in the blood donor populations, as previously described. 24 Of these 161 samples, 102 were available in sufficient quantities to allow repeat PCR analysis. Of these 102 samples analyzed, 67 (65.7%) gave HCV-specific positive signals by PCR of the 5'-UTR of HCV. Genotype analysis was performed on the HCV RNA-positive samples. Data obtained on the genotyping analysis of 64 of these samples using the typespecific primers outlined in the Materials and Methods are summarized in Table 2 . Fifty-seven of the 64 samples analyzed appeared to be readily classified as those belonging to individual genotypes 1a, 1b, 2a, and 3b. Three samples appeared to contain 2 or more genotypes and 4 gave indeterminate results. Of the 57 that were readily classified into genotypes, 37 were typed as genotype 1b, 11 as genotype 2a, and 7 as genotype 3b. One sample each were typed as genotypes 1a and 2b. The predominant HCV genotype in this donor population were genotypes 1b, 2a, and 3b, accounting for 55 of the single genotype samples and 57 if one includes those samples with multiple genotypes. A typical electrophoretic pattern of the PCR products showing different genotypes is shown in Figure 1 .
The 4 indeterminate HCV samples listed in Table 2 were sequenced as described in the Materials and Methods (samples NMR2A9-1, NMR2A42-1, NMR2A46-2, and NMRA75-5), and their sequences aligned with the published sequences of various known HCV genotypes including 1a, 1b, 3 of 1c, 2a, 2b, 2c, 2d, 3a, 3b, 4a, 5a, 6a, 7a, 10a, and 11a. The core sequences of the indeterminant samples NMR2A9-1, NMR2A42-1, NMR2A46-2, and NMR2A75-5 are listed in Table 3 . The comparative analysis of the indeterminate samples with previously reported genotype sequences is shown in Table  4 . As seen, the degree of homology for each of the indeterminates varied from 95.16% to 78.67%.
It is important to note that the majority (86 of 102) of the samples were derived from individuals residing in the islands of Java and Bali. However, a few (16 of 102) samples were also available from the other islands of the Indonesian archipelago. Although the number is small, except for a single case of subtype 2b from a blood donor in Kalimantan, subtype 1b was identified in all other positive samples and no other subtypes were identified from outside the island of Java. Subtype 1b was found in 59% of the HCV RNA-positive samples from the island of Java. This subtype was also the only subtype identified in positive samples from Sumatra, Kalimantan, Sulawesi, and eastern Indonesia. The subtype distribution within the Indonesian archipelago is shown in Figure 2 . 
DISCUSSION
Previous studies 26, 27 on clinically diagnosed patients with hepatitis documented a prevalence rate of 44% HCV seropositive samples with genotype 1b. However, it was reasoned that these data may have been biased towards the HCV genotypes that cause the most clinically severe form of the disease and were not a true reflection of the genotypes and variants of HCV prevalent within the Indonesian archipelago. In efforts to provide a more non-biased sampling of the prevalence of HCV genotypes and variants in Indonesia, a study was conducted on blood bank donors. The results of these studies are reported herein. Several issues need to be addressed. First, the results of our data (Table 2) showed that similar to the prevalence of a high frequency of the 1b and 2a HCV genotypes (44% and 26%, respectively) in the patients with hepatitis, the 1b and 2a genotypes were present at high frequencies (57.8% and 17.2%, respectively) in the blood donor population in the studies reported herein. However, in contrast to the other genotypes, some notable differences exist. Thus, whereas HCV genotype 1c was significantly associated with clinically ill hepatitis patients (12%), the 3b HCV genotype was significantly prevalent (10.9%) in the blood donor population. The interpretation of these findings await more large-scale studies with a larger number of samples in efforts to determine whether these differences signify genotypes that induce disease and asymptomatic infections.
The pattern of distribution of the various HCV genotypes in the blood donor population in Indonesia basically reflects patterns observed in Asia. 5 Analysis of data published appear to indicate that only 5 of the HCV genotypes (1a, 1b, 2a, 2b, and 3a) are prevalent in most parts of the world. Of these, genotype 1b is the one mostly associated with clinical disease and relatively refractory in its response to therapy with interferon-alpha. However, as alluded to earlier, it remains to be seen whether there are other genotypes that share this characteristic. Thus, continued efforts need to be made in identifying the various genotypes of HCV and the clinical-epidemiologic characteristics recorded to permit such an evaluation. It is also important to keep in mind that our criteria for classifying the genotypes may need to be reevaluated. Thus, of importance would be not only the sequence diversity data, but also the putative sequences that result in clinically relevant outcomes such as disease pathogenesis and those that may induce immune responses to prevent infection or at least disease. It is to be noted that the predominant number of samples analyzed were obtained from the blood donor population from the islands of Java and Bali. Analysis of a few positive isolates from the other islands of the Indonesian archipelago showed that most of these belonged to the HCV 1b genotype. Again, more detailed studies of a larger number of samples is required before any claims can be made regarding the genotype prevalence of HCV in the other Indonesian islands.
One other issue that needs to be addressed is the reason for the isolation and genotype identification of only 67 of the 102 HCV seropositive samples in the studies reported herein. It is reasoned that this is most likely due to any of the 3 following reasons or a combination thereof. It is possible that the individuals who were seropositive but failed to show the presence of the virus was due to the fact that the individuals were infected some time ago and had cleared their viremia prior to sample procurement. This is likely to be the most reasonable explanation for the data obtained. However, it is also possible that the failure to identify HCV in these samples was due to the limits of the sensitivity of the techniques used due to the unusual occurrence of variants that have sufficient differences in the regions of the primers and/or probes being used. Finally, it is possible that the EIA showed reactivity that was in fact false positive. Unfortunately, follow-up samples from these individuals were not available to distinguish among these possibilities. Finally, the significance of the results of the sequence alignments of the 4 indeterminate HCV samples needed to be addressed. Based on an arbitrary judgment, it appears that samples NMR2A9-1, NMR2A42-1, and NMR2A46-2 have the highest degree of homology with genotype 1c. Sample NMR2A75-5 appears to be the most divergent of the 4 indeterminate HCVs. Clearly, additional sequencing studies of these indeterminates and their alignment with corresponding known sequences in the available database need to be performed to gain further insights into the diversity of HCV isolates.
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